Effects of excess high-normal alanine aminotransferase levels in relation to new-onset metabolic dysfunction-associated fatty liver disease: Clinical implications

doi:10.3748/wjg.v30.i27.3264

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 30, Issue 27

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (944)

All Articles published online

The chart showing PDF series, HTML series.

Item

Count

PDF

HTML

775

Sum=801

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

Download

Sum=65

Jul 21, 2024 (publication date) through Sep 8, 2024

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Editorial

World J Gastroenterol. Jul 21, 2024; 30(27): 3264-3267
Published online Jul 21, 2024. doi: 10.3748/wjg.v30.i27.3264

Effects of excess high-normal alanine aminotransferase levels in relation to new-onset metabolic dysfunction-associated fatty liver disease: Clinical implications

Giovanna McGinty, Robert Przemioslo

Giovanna McGinty, Department of Gastroenterology, North Bristol Trust, Southmead Hospital, Bristol BS10 5NB, United Kingdom

Robert Przemioslo, Department of Gastroenterology and Hepatology, North Bristol Trust, Southmead Hospital, Bristol BS10 5NB, United Kingdom

Author contributions: McGinty G and Przemioslo R contributed, designed the overall concept and contributed to writing, editing and review of the literature.

Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.

Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

Corresponding author: Giovanna McGinty, MBChB, MSc, Doctor, Department of Gastroenterology, North Bristol Trust, Southmead Hospital, Southmead Road, Bristol BS10 5NB, United Kingdom. giovanna.sheiybani@nhs.net

Received: March 11, 2024
Revised: May 29, 2024
Accepted: June 21, 2024
Published online: July 21, 2024
Processing time: 121 Days and 14.4 Hours

Core Tip

Core Tip: Alanine aminotransferase (ALT) is a surrogate marker for metabolic-dysfunction associated fatty liver disease (MAFLD) but is not specific for histological inflammation. The rationale to reduce the upper limit of normal for ALT to help identify more cases of MAFLD remains controversial. It is more important to identify patients who may display elements of the metabolic syndrome and support modifying these to maintain a lower level of ALT. This will become increasingly important as more targets for therapy are identified that may justify treating these patients early to prevent progression to fibrosis.